Artia Global Partners LP Purchases New Holdings in Celcuity, Inc. $CELC

Artia Global Partners LP purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) in the 4th quarter, Holdings Channel reports. The fund purchased 12,900 shares of the company’s stock, valued at approximately $1,287,000.

Other large investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its position in Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares during the last quarter. US Bancorp DE boosted its position in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after purchasing an additional 1,167 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Celcuity during the fourth quarter valued at approximately $42,000. Finally, Ogorek Anthony Joseph NY ADV boosted its position in Celcuity by 19.7% during the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after purchasing an additional 109 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CELC has been the subject of several recent research reports. Craig Hallum reduced their price target on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. Wells Fargo & Company reduced their price target on Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. HC Wainwright dropped their price objective on Celcuity from $185.00 to $145.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Stifel Nicolaus set a $150.00 target price on Celcuity in a research note on Monday, May 4th. Finally, Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Eleven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Celcuity has an average rating of “Moderate Buy” and an average price target of $152.09.

Celcuity Stock Up 0.8%

CELC stock opened at $88.05 on Thursday. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04. The firm has a market capitalization of $4.29 billion, a PE ratio of -22.58 and a beta of 0.10. Celcuity, Inc. has a 1-year low of $11.27 and a 1-year high of $151.02. The business’s 50 day simple moving average is $118.29 and its 200 day simple moving average is $111.04.

Celcuity (NASDAQ:CELC) last posted its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. As a group, research analysts anticipate that Celcuity, Inc. will post -3.69 EPS for the current year.

Insider Buying and Selling

In related news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director directly owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. The trade was a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 37,000 shares of company stock worth $5,111,950 over the last three months. 13.33% of the stock is owned by insiders.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.